

# Luis L Ostrosky-Zeichner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4686312/publications.pdf>

Version: 2024-02-01

135  
papers

20,408  
citations

34105

52  
h-index

18647

119  
g-index

137  
all docs

137  
docs citations

137  
times ranked

13013  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. <i>JAMA Internal Medicine</i> , 2022, 182, 115.	5.1	63
2	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	25
3	Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non <i>Aspergillus fumigatus</i> ): A multicentre, non-interventional registry study. <i>Mycoses</i> , 2022, 65, 186-198.	4.0	7
4	Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e3647-e3655.	5.8	75
5	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e149-e162.	9.1	586
6	Reprocessing N95s with hydrogen peroxide vaporization: A robust system from collection to dispensing. <i>American Journal of Infection Control</i> , 2021, 49, 508-511.	2.3	1
7	Candidemia: An Infection Prevention Issue?. <i>Clinical Infectious Diseases</i> , 2021, 73, 697-698.	5.8	1
8	Screening donors for COVID-19 convalescent plasma. <i>Transfusion</i> , 2021, 61, 1047-1052.	1.6	8
9	Lymphatic Dissemination and Axillary Web Syndrome in Primary Cutaneous Tuberculosis Secondary to Needlestick Injury. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab160.	0.9	4
10	Furuncular myiasis in a traveller to West Africa. <i>Journal of Travel Medicine</i> , 2021, 28, .	3.0	1
11	Investigational Agents for the Treatment of Resistant Yeasts and Molds. <i>Current Fungal Infection Reports</i> , 2021, 15, 104-115.	2.6	18
12	The New Medical Mycology. <i>Infectious Disease Clinics of North America</i> , 2021, 35, xiii-xiv.	5.1	0
13	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e375-e386.	9.1	80
14	Coronavirus Disease 2019-Associated Invasive Fungal Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab510.	0.9	75
15	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
16	Measles or Not Measles? That is the Question!. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa311.	0.9	0
17	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020, 222, S175-S198.	4.0	83
18	Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2020, 49, 77.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Invasive Candidiasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 003-012.	2.1	45
20	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3056-3062.	3.0	54
21	Seroprevalence of <i>Strongyloides stercoralis</i> and Evaluation of Universal Screening in Kidney Transplant Candidates: A Single-Center Experience in Houston (2012-2017). <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.9	17
22	Point-Counterpoint: Should Serum $\beta$ -D-Glucan Testing Be Used for the Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia?. <i>Journal of Clinical Microbiology</i> , 2019, 58, .	3.9	11
23	Prevention and Treatment of Yeast and Endemic Fungal Infections. , 2019, , 179-199.		0
24	Update on the Diagnosis of Candidemia and Invasive Candidiasis. <i>Current Fungal Infection Reports</i> , 2019, 13, 301-307.	2.6	3
25	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1981-1989.	5.8	120
26	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. <i>Mycoses</i> , 2018, 61, 485-497.	4.0	24
27	Isavuconazole for treatment of rare invasive fungal diseases. <i>Mycoses</i> , 2018, 61, 518-533.	4.0	32
28	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. <i>Clinical Infectious Diseases</i> , 2018, 66, 1678-1686.	5.8	129
29	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. <i>Mycoses</i> , 2018, 61, 420-429.	4.0	25
30	113. Accuracy of the NHSN Central Line-Associated Bloodstream Infection (CLABSI) Definition. <i>Open Forum Infectious Diseases</i> , 2018, 5, S3-S3.	0.9	4
31	369. Using Hybrid Models and Blockchain Technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S144-S145.	0.9	1
32	2045. Pitfalls in the Use of MALDI TOF Mass Spectrometry for the Identification of Problematic Yeast Isolates from a Historical Collection. <i>Open Forum Infectious Diseases</i> , 2018, 5, S596-S597.	0.9	0
33	1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, S52-S52.	0.9	5
34	Post-exposure prophylaxis with isavuconazole after occupational exposure to <i>Rhizopus</i> . <i>Oxford Medical Case Reports</i> , 2018, 2018, omy062.	0.4	4
35	<i>In Vitro</i> Evaluation of Bact/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of <i>Candida</i> in the Presence of Antifungals. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	17
36	A Risk Score for Fluconazole Failure among Patients with Candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	12

#	ARTICLE	IF	CITATIONS
37	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. <i>Intensive Care Medicine</i> , 2017, 43, 1225-1238.	8.2	123
38	Drugs in Clinical Development for Fungal Infections. <i>Drugs</i> , 2017, 77, 1505-1518.	10.9	58
39	Thinking beyond the Common Candida Species: Need for Species-Level Identification of Candida Due to the Emergence of Multidrug-Resistant <i>Candida auris</i> . <i>Journal of Clinical Microbiology</i> , 2017, 55, 3324-3327.	3.9	49
40	Progressive Dispersion of Azole Resistance in <i>Aspergillus fumigatus</i> : Fatal Invasive Aspergillosis in a Patient with Acute Myeloid Leukemia Infected with an <i>A. fumigatus</i> Strain with a <i>cyp51A</i> TR<sub>46</sub> Y121F M172I T289A Allele. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	10
41	Invasive Fungal Infections in the Intensive Care Unit. <i>Infectious Disease Clinics of North America</i> , 2017, 31, 475-487.	5.1	49
42	The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus. <i>Journal of Infectious Diseases</i> , 2017, 216, S452-S457.	4.0	14
43	Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel. <i>Open Forum Infectious Diseases</i> , 2017, 4, S52-S52.	0.9	0
44	Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis. <i>BMC Infectious Diseases</i> , 2017, 17, 753.	2.9	15
45	A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx200.	0.9	43
46	Don't Pace Right Past the Sink: Electrophysiology Sterility Practices in the Face of Absent Guidelines. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
47	A marginal structural approach to measuring the comparative effectiveness of echinocandins Versus fluconazole therapy for the treatment of adult candidemia (MSG-12). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
48	Epidemiology and Natural History of Non-Tuberculous Mycobacterial Surgical Sites Infections. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
49	Epidemiology and Management of Candidiasis in Solid Organ Transplant Recipients. <i>Current Fungal Infection Reports</i> , 2016, 10, 147-152.	2.6	2
50	Fungal Diagnostics: A Practical Approach. <i>Current Clinical Microbiology Reports</i> , 2016, 3, 103-110.	3.4	0
51	Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to <i>Candida parapsilosis</i> : a retrospective observational cohort study of the Mycoses Study Group (MSG-12): Table A1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3536-3539.	3.0	37
52	40 years of medical mycology at JAC. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3327-3329.	3.0	0
53	Clinical Characteristics and Predictors of Adverse Outcome in Adult and Pediatric Patients With Healthcare-Associated Ventriculitis and Meningitis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw077.	0.9	39
54	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, 409-417.	5.8	1,258

#	ARTICLE	IF	CITATIONS
55	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	9.1	528
56	Fungal Infections. <i>Infectious Disease Clinics of North America</i> , 2016, 30, xiii-xiv.	5.1	3
57	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, e1-e50.	5.8	2,489
58	Tigecycline: a critical safety review. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 335-342.	2.4	70
59	Cefepime free minimum concentration to minimum inhibitory concentration (fC <sub>min</sub> /MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 541-544.	2.5	58
60	T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 892-899.	5.8	369
61	Antifungal Susceptibility Testing: Evolution, Indications, and Role in Clinical Practice. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 155-162.	1.9	2
62	Surveillance of <i>Candida</i> spp Bloodstream Infections: Epidemiological Trends and Risk Factors of Death in Two Mexican Tertiary Care Hospitals. <i>PLoS ONE</i> , 2014, 9, e97325.	2.5	30
63	MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting. <i>Clinical Infectious Diseases</i> , 2014, 58, 1219-1226.	5.8	142
64	What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. <i>Intensive Care Medicine</i> , 2014, 40, 808-819.	8.2	90
65	Editorial Commentary: <i>Candida glabrata</i> and FKS Mutations: Witnessing the Emergence of the True Multidrug-Resistant <i>Candida</i> . <i>Clinical Infectious Diseases</i> , 2013, 56, 1733-1734.	5.8	43
66	Correlation of Clinical Outcomes with $\beta$ -Glucan Levels in Patients with Invasive Candidiasis. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2104-2106.	3.9	51
67			

#	ARTICLE	IF	CITATIONS
73	Clinical breakpoints for voriconazole and <i>Candida</i> spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 330-343.	1.8	117
74	Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. <i>Mycoses</i> , 2011, 54, 46-51.	4.0	98
75	High-Dose Caspofungin is Safe for Adult Patients with Invasive Candidiasis. <i>Current Fungal Infection Reports</i> , 2011, 5, 1-2.	2.6	1
76	Prospective Survey of (1 $\alpha$ ) <sup>3</sup> - $\beta$ -Glucan and Its Relationship to Invasive Candidiasis in the Surgical Intensive Care Unit Setting. <i>Journal of Clinical Microbiology</i> , 2011, 49, 58-61.	3.9	96
77	Multilaboratory Testing of Two-Drug Combinations of Antifungals against <i>Candida albicans</i> , <i>Candida glabrata</i> , and <i>Candida parapsilosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1543-1548.	3.2	38
78	Early antifungal intervention strategies in ICU patients. <i>Current Opinion in Critical Care</i> , 2010, 16, 465-469.	3.2	26
79	An insight into the antifungal pipeline: selected new molecules and beyond. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 719-727.	46.4	360
80	Invasive Candidiasis in the Intensive Care Unit. <i>Hospital Practice (1995)</i> , 2010, 38, 82-91.	1.0	1
81	Activity of Anidulafungin in a Murine Model of <i>Candida krusei</i> Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)- $\beta$ -Glucan Levels. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1639-1641.	3.2	11
82	Can fungal biomarkers be used to improve antifungal therapy in the intensive care unit?. <i>Current Fungal Infection Reports</i> , 2009, 3, 147-151.	2.6	0
83	Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2009, 48, 503-535.	5.8	2,644
84	Issues in the design and interpretation of antifungal drug trials in the critically ill. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 564-567.	3.1	5
85	Fungal and Parasitic Infections. , 2009, , 113-134.		1
86	Prophylaxis for <i>Candida</i> in the intensive care unit patient. <i>Current Fungal Infection Reports</i> , 2008, 2, 69-73.	2.6	0
87	Current Options in Antifungal Pharmacotherapy. <i>Pharmacotherapy</i> , 2008, 28, 614-645.	2.6	68
88	Antifungal and Antiviral Therapy. , 2008, , 1089-1109.		2
89	Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing <i>Candida</i> spp. by the CLSI M27-A2 Standard Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4175-4177.	3.2	40
90	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. <i>Clinical Infectious Diseases</i> , 2008, 47, 674-683.	5.8	368

#	ARTICLE	IF	CITATIONS
91	Multilaboratory Testing of Antifungal Combinations against a Quality Control Isolate of <i>Candida krusei</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1500-1502.	3.2	28
92	Pharmacokinetic Evaluation of Single-Dose Intravenous Daptomycin in Patients with Thermal Burn Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1891-1893.	3.2	57
93	Neonatal Fungal Infections. , 2008, , 262-278.		1
94	Effects of Serum on In Vitro Susceptibility Testing of Echinocandins. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4214-4216.	3.2	67
95	Anidulafungin: a new addition to the antifungal armamentarium. <i>Therapy: Open Access in Clinical Medicine</i> , 2007, 4, 125-132.	0.2	1
96	Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. <i>Lancet, The</i> , 2007, 369, 1519-1527.	13.7	1,185
97	Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis. <i>Clinical Infectious Diseases</i> , 2007, 45, 883-893.	5.8	1,115
98	Contemporary Treatment and Outcomes of Zygomycosis in a Non-oncologic Tertiary Care Center. <i>Archives of Medical Research</i> , 2007, 38, 90-93.	3.3	35
99	Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2007, 26, 271-276.	2.9	325
100	Invasive Yeast Infections. <i>Infectious Disease and Therapy</i> , 2007, , 221-238.	0.0	1
101	Differences in beta-glucan levels in culture supernatants of a variety of fungi. <i>Medical Mycology</i> , 2006, 44, 267-272.	0.7	121
102	Invasive candidiasis in the intensive care unit. <i>Critical Care Medicine</i> , 2006, 34, 857-863.	0.9	217
103	Correlation between Microdilution, E-test, and Disk Diffusion Methods for Antifungal Susceptibility Testing of Posaconazole against <i>Candida</i> spp. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2105-2108.	3.9	39
104	Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 143-147.	3.2	153
105	Invasive Candidiasis in Immunocompromised Hospitalized Patients. <i>Archives of Medical Research</i> , 2005, 36, 660-671.	3.3	105
106	Fatal Amphotericin B Overdose Due to Administration of Nonlipid Formulation Instead of Lipid Formulation. <i>Pharmacotherapy</i> , 2005, 25, 426-428.	2.6	21
107	Successful Use of Amphotericin B Lipid Complex in the Treatment of Cryptococcosis. <i>Clinical Infectious Diseases</i> , 2005, 40, S409-S413.	5.8	46
108	Syscan3, a Kit for Detection of Anti- <i>Candida</i> Antibodies for Diagnosis of Invasive Candidiasis. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4834-4835.	3.9	25

#	ARTICLE	IF	CITATIONS
109	Multicenter Clinical Evaluation of the (1-&gt;3) $\beta$ -D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans. <i>Clinical Infectious Diseases</i> , 2005, 41, 654-659.	5.8	640
110	Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. <i>Medical Mycology</i> , 2005, 43, 235-243.	0.7	165
111	Pharmacoeconomics of antifungal pharmacotherapy â€œ challenges and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2617-2632.	1.8	24
112	Cost of a Ventilator-Associated Pneumonia in a Shock Trauma Intensive Care Unit. <i>Surgical Infections</i> , 2005, 6, 65-72.	1.4	74
113	In Vitro Synergy Testing of Anidulafungin with Itraconazole, Voriconazole, and Amphotericin B against <i>Aspergillus</i> spp. and <i>Fusarium</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3572-3574.	3.2	76
114	Novel approaches to antifungal prophylaxis. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 665-672.	4.1	3
115	Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against <i>Candida</i> and <i>Aspergillus</i> Species. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3475-3482.	3.9	174
116	Pharmacokinetics of Intravenous Itraconazole in Stable Hemodialysis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3151-3153.	3.2	31
117	In Vitro Activity of Anidulafungin against Selected Clinically Important Mold Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1912-1915.	3.2	82
118	Therapy of common superficial fungal infections. <i>Dermatologic Therapy</i> , 2004, 17, 517-522.	1.7	23
119	$\beta$ -D-Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cutoff Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Clinical Infectious Diseases</i> , 2004, 39, 199-205.	5.8	610
120	Associations between antibiotic use and changes in susceptibility patterns of in a private, university-affiliated teaching hospital: an 8-year-experience: 1995?2002. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 346-351.	2.5	26
121	Combination Antifungal Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 693-715.	3.2	478
122	Antifungal Susceptibility Survey of 2,000 Bloodstream <i>Candida</i> Isolates in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3149-3154.	3.2	493
123	Peritonitis due to <i>Aspergillus</i> and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 46, 49-54.	1.8	44
124	Correlation between E-Test, Disk Diffusion, and Microdilution Methods for Antifungal Susceptibility Testing of Fluconazole and Voriconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1647-1651.	3.2	221
125	Amphotericin B: Time for a New "Gold Standard". <i>Clinical Infectious Diseases</i> , 2003, 37, 415-425.	5.8	350
126	New approaches to the risk of <i>Candida</i> in the intensive care unit. <i>Current Opinion in Infectious Diseases</i> , 2003, 16, 533-537.	3.1	73



#	ARTICLE	IF	CITATIONS
127	In Vitro Activities of Investigational Triazoles against Fusarium Species: Effects of Inoculum Size and Incubation Time on Broth Microdilution Susceptibility Test Results. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3298-3300.	3.2	74
128	In Vitro Activity of Nystatin Compared with Those of Liposomal Nystatin, Amphotericin B, and Fluconazole against Clinical Candida Isolates. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1406-1412.	3.9	41
129	Effect of the Echinocandin Caspofungin on Expression of Candida albicans Secretory Aspartyl Proteinases and Phospholipase In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3096-3100.	3.2	26
130	In Vitro Antifungal Susceptibilities of Trichosporon Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1144-1146.	3.2	184
131	Deeply invasive candidiasis. <i>Infectious Disease Clinics of North America</i> , 2002, 16, 821-835.	5.1	55
132	Differential Antifungal Activity of Isomeric Forms of Nystatin. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2781-2786.	3.2	16
133	Liposuction for protease-inhibitor-associated lipodystrophy. <i>Lancet</i> , The, 1999, 353, 1244.	13.7	47
134	Neurocysticercosis and HIV infection: Report of two cases and review. <i>World Neurosurgery</i> , 1996, 45, 57-61.	1.3	34
135	New Developments in Diagnostics and Management of Invasive Candidiasis. , 0, , 443-448.		0